BioPharma Dive July 30, 2024
The company is letting go of 150 staffers alongside a decision to officially terminate the formerly high-profile program, which missed all of its objectives in a Phase 3 trial last month.
Pfizer has officially given up on an experimental gene therapy for Duchenne muscular dystrophy and will lay off staff involved in the project, the company confirmed Tuesday.
“In light of the disappointing results” Pfizer disclosed from a Phase 3 study in June, the company “does not have plans to continue development” of the therapy, a spokesperson wrote in an email to BioPharma Dive.
Pfizer will continue to monitor all participants treated in studies of the therapy, and is “committed to sharing detailed results” at medical and patient advocacy meetings...
Today's Sponsors
Today's Sponsor